Studies have demonstrated that dacomitinib has a potent efficacy in patients with NSCLC carrying brain metastases [36,37], and this has been specifically confirmed in patients with uncommon EGFR mutations [17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.